Ocular Therapeutix develops eye treatments, including AXPAXLI, an investigational drug in trials for eye diseases, and sells DEXTENZA. OCUL reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints.
Prices, price targets and earnings estimates for OCUL are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCUL is in one of them and how their past OCUL trades turned out.
Ocular Therapeutix is a biopharmaceutical company based in Bedford, Massachusetts, that develops and sells treatments for eye conditions. Its lead investigational product, AXPAXLI, is a drug delivered into the eye through a gel that dissolves over time, and it is being tested for wet macular degeneration and diabetic retinal disease. The company also sells DEXTENZA, an FDA-approved insert used to treat eye pain and inflammation after surgery and itching from allergic conjunctivitis.
